

EXHIBIT 3

weeks and it is preferable to err on the longer interval than a shorter one. The interval between the second and third injections should be even longer, with at least five or six months in between. Again, it is better to err on the longer interval. This schedule makes the original fourth booster dose in the second year of life no longer necessary.

If a potent adjuvant DTP vaccine is used with the intervals between the first and second doses as stated, the interval between the second and third can be as long as 9 to 12 months with an adequate response, but it is always preferable to keep to the recommended schedule ('Immunisation Against Infectious Diseases', issued by the Department of Health and Social Security, Alexander Fleming House, Elephant and Castle, London SE1 6RY, July 1972).

PROFESSOR J. A. DUGGON, M.C., T.D.,
M.D., M.R.C.P.

Black Hairy Tongue

QUERY (from a reader in Malta).—I should be grateful if you could tell me whether there are any new findings on the cause and treatment of 'black hairy tongue'.

A married woman, aged 49 years, who had a total hysterectomy two years ago for metropathia haemorrhagica, has developed a black hairy tongue during the past nine months. The tongue is covered in black hair in the centre towards the back; she complains of a taste of mud. She shows no other signs of the menopause.

After having undergone various courses of antifungal and vitamin treatment she is now very distressed about her condition.

REPLY.—Black hairy tongue may follow the use of local or systemic antibiotics or occur without obvious cause. Regular gentle brushing with a soft toothbrush may be effective in removing the hypertrophied papillae. Tomaszewski (1953) reported that antibiotic lozenges, while causing the colour of the tongue to deepen for a few days, make the hairs more easy to remove.

I am not aware of any new findings on the cause or treatment of this distressing condition.

Reference

Tomaszewski, W. (1953): *Brit. med. J.*, **1**, 1249.
R. H. BALME, D.M., F.R.C.P.

Interruption of Oral Contraception

QUERY.—With regard to the contraceptive pill, at one time it was the practice that this should be discontinued for a month each year in women wishing further family. Is this now considered necessary?

REPLY.—It has never been accepted practice to advise women using oral contraceptives to stop them unless they wished to have a family, the need for contraception had ceased, or contraindications to further use of the pill had arisen. It seems that the confusion which still exists on this point arose from the fact that, when the Food and Drugs Administration of the USA first licensed oral contraceptives for clinical use they stipulated that this was to be for a period of two years. On reviewing the position at the end of that time, the licence was extended for a further two years. A second review, at the end of four years' experience, led the FDA to withdraw the time limit altogether. The accumulated experience of some 15 years of clinical use of oral contraceptives has failed to show that any advantage accrues from interrupting the use of the pill, other than for the reasons mentioned above.

G. I. M. SWYER, D.M., F.R.C.P.

Research on Anticarcinogenic Effects of Thalidomide

QUERY.—While carrying out a literature survey for my research into 'drug complex formation' it occurred to me that teratogenic drugs such as thalidomide should be of value in the treatment of cancer. As a physicist my knowledge in this field is very limited and I would appreciate the opinion of your medical experts.

REPLY.—It is well known that some teratogens exhibit tumour-inhibitory activity and may also be mutagens and/or carcinogens. It is not surprising therefore that the above question has arisen in the minds of others (Hunter, 1962; Rogerson, 1962). Workers at the Chester Beatty Research Institute (Roe and Mitchley, 1963) saw no inhibition of the growth of the transplantable Walker tumour in rats in response to thalidomide. Bach and his colleagues (1963) obtained

This material is subject to United States copyright law; further reproduction in violation of that law is prohibited.

negative results in mice to mice bearing a transplantable tumour. They found thalidomide to be eight times as effective as cyclophosphamide in inhibiting the growth of eight transplantable tumours. Thalidomide may have a direct antineoplastic activity (Roe *et al.*, 1967) but is not mutagenic for *Drosophila*. The various laboratory tests have shown no encouragement. Thalidomide might be of value in the treatment of human cancer. Two clinical trials (Grunbaum and Golbey, 1962) in 92 cancer patients showed that thalidomide had no significant antineoplastic activity.

Re
Bach, A., Bichel, J., and
1, 1271.
Diffole, J. A. (1963): *C*
Grabald, H., and Coll
6, 290.
Hunter, T. A. A. (1962)
Larsen, H. (1962): *Id.*
Olson, K. B., Hall, T. C.
Hosley, H. V. (1962)
Roe, J. J., and Mit
(Lond.), 220, 1016.
Rogerson, G. (1962): *L*
Walters, M. A.,
Brit. J. Cancer, 21, 3
F. J. C. ROE,

Behçet's Syndrome

QUERY (from a reader).—An old man has had recurrent oral and genital ulcers, conjunctivitis, and arthritis of the knees, and all without urethral discharge. He has grade fever and joint pains. He has Behçet's syndrome. What is the best treatment for the symptoms for the condition? He has been given antibiotics, local treatment, and Prednisone tablets. The condition relapses. The condition is reduced. I should be grateful for your opinion.

REPLY.—The condition is certainly consistent with Behçet's syndrome—a condition which no treatment has yet been found to cure. Before finally accept-

NOTES AND QUERIES

297

Oral

d to the contraceptive was the practice that continued for a month wishing further family. ed necessary?

er been accepted prac- en using oral contra- n unless they wished to need for contraception rindications to further risen. It seems that the ll exists on this point that, when the Food ration of the USA first optives for clinical use this was to be for a

re. On reviewing the of that time, the licence further two years. A he end of four years' FDA to withdraw the cr. The accumulated 15 years of clinical use has failed to show crues from interrupting her than for the reasons

I. SWYER, D.M., F.R.C.P.

Icarcinogenic
lomid

ying out a literature ch into 'drug complex d to me that teratogenic idomide should be of ent of cancer. As a dge in this field is very appreciate the opinion erts.

own that some terato- inhibitory activity and ns and/or carcinogens. herefore that the above in the minds of others rson, 1962). Workers ity Research Institute :963) saw no inhibition ransplantable Walker sponse to thalidomide. gues (1963) obtained

negative results when they gave thalido- mide to mice bearing either of two trans- plantable tumours, and DiPaolo (1963) found thalidomide to be ineffective against eight transplantable tumours in mice. Thalidomide may exhibit feeble carcino- genic activity (Roe and Mitchley, 1963; Roe *et al.*, 1967) but is not apparently mutagenic for *Drosophila* (Lucas, 1962). The various laboratory findings provided no encouragement for the view that thalido- mide might be of practical value in the treatment of human cancer. Furthermore, two clinical trials (Olson *et al.*, 1965; Grab- stald and Golbey, 1965) involving a total of 92 cancer patients revealed no real evidence that thalidomide exhibited useful anti- cancer activity although the drug had sig- nificant palliative value.

References

- Beck, A., Bichel, J., and Hejgaard, J. J. (1963): *Lancet*, **1**, 1371.
DiPaolo, J. A. (1963): *Cancer Chemother. Rep.*, **29**, 99.
Grabstald, H., and Golbey, R. (1965): *Clin. Pharmacol.*, **6**, 398.
Hunter, T. A. A. (1962): *Lancet*, **ii**, 400.
Lucas, H. (1962): *Ibid.*, **ii**, 1333.
Olson, K. B., Hall, T. C., Horton, J., Khung, C. Y., and Hoxley, H. F. (1965): *Clin. Pharmacol.*, **6**, 293.
Roe, P. J. C., and Mitchley, R. C. V. (1963): *Nature (Lond.)*, **200**, 1916.
Hogkinson, G. (1962): *Lancet*, **i**, 691.
Walters, M. A., and Mitchley, R. C. V. (1967): *Brit. J. Cancer*, **21**, 331.

F. J. C. ROE, D.M., D.Sc., F.R.C.PATH.

Behçet's Syndrome

QURRY (from a reader in Iraq).—A 30-year- old man has had repeated attacks of stomati- tis, ulcerative eye lesions involving the conjunctivae and uveal tract, ulceration on the genitalia, and also pelvic ulceration, but without urethral discharge. He also has low- grade fever and joint pain. The picture sug- gests Behçet's syndrome. He has had these symptoms for the past 2½ years and has been given antibiotics by mouth and in- jection, local treatment to the eye, and Prednisone tablets. Remissions occur but the condition relapses if the dosage of drugs is reduced. I should appreciate an expert opinion.

Reply.—The clinical features of this case are certainly consistent with Behçet's syn- drome—a condition of unknown etiology for which no treatment is of proven value. Before finally accepting such a diagnosis, it

would be as well to make sure that the blood count is normal, since chronic leu- copenia may present in this way in associa- tion with splenomegaly in some cases and with rheumatoid arthritis in others (Felty's syndrome) or as part of systemic lupus erythematosus, and most of these conditions respond to steroids. Careful examination of the gastrointestinal tract also would be indicated to exclude ulcerative colitis or possibly Crohn's disease in this case and it should be remembered that sensitivity to drugs (especially Phenyl- butazone or Sulphonamides) could produce these symptoms.

If none of these conditions is present, the diagnosis of Behçet's syndrome may be accepted. The condition does not always respond to steroids, and antibiotics are not helpful except in the treatment of definite bacterial complications such as pneu- monia. The combination of long-term anti- biotics and steroids would be particularly likely to lead to opportunistic infection with unusual antibiotic-resistant organisms of low virulence, especially fungi. It would be important to correct any nutritional deficiencies, especially of water-soluble vitamins or protein. Local treatment with Hydrocortisone pellets may help the mouth lesions.

In this particular patient, if there is a clear-cut remission of symptoms and im- provement in signs on oral Prednisone this drug may have to be continued indefinitely. Once the remission is induced the Pred- nisone dosage should be reduced very gradually. If the initial dosage has had to be high, e.g. 60 mg a day, it will generally be possible to cut it by 5 mg every other day until a level of about 20 mg is reached. Thereafter an even more gradual reduction in dosage would be necessary and reductions of 1 mg in the daily dose every four days or so is suggested. In this way it may be pos- sible to reach a low maintenance dose. A dose of less than 10 mg a day of Prednisone should not produce severe side-effects and 10 to 20 mg a day may be well tolerated pro- vided the patient remains physically active and takes a diet with adequate protein, vitamins and calcium content. Much larger doses can be tolerated for short periods.

R. H. BALME, D.M., F.R.C.P.